The spike proteins of coronaviruses are capable of binding to a wide range of cellular 25 targets, which contribute to the broad species tropism of coronaviruses. Previous reports 26 have demonstrated that Middle East respiratory syndrome coronavirus (MERS-CoV) 27 predominantly utilizes dipeptidyl peptidase-4 (DPP4) for cell entry. However, additional 28 cellular binding targets of the MERS-CoV spike protein that may augment MERS-CoV 29 infection have not been further explored. In the current study, using the virus overlay 30 protein binding assay (VOPBA), we identified carcinoembryonic antigen-related cell 31 adhesion molecule 5 (CEACAM5) as a novel cell surface binding target of MERS-CoV. 32 CEACAM5 co-immunoprecipitated with the spike protein of MERS-CoV in both 33 overexpressed and endogenous settings. Disrupting the interaction between CEACAM5 34 and MERS-CoV spike with anti-CEACAM5 antibody, recombinant CEACAM5 protein, 35 or siRNA knockdown of CEACAM5 significantly inhibited the entry of MERS-CoV. 36 Recombinant expression of CEACAM5 did not render the non-permissive baby hamster 37 kidney (BHK21) cells susceptible to MERS-CoV infection. Instead, CEACAM5 38 overexpression significantly enhanced the attachment of MERS-CoV to the BHK21 cells. 39 More importantly, the entry of MERS-CoV was increased when CEACAM5 was 40 overexpressed in permissive cells, which suggested that CEACAM5 could facilitate 41 MERS-CoV entry in conjunction with DPP4 despite not being able to support MERS-42 CoV entry independently. Taken together, our study identified CEACAM5 as a novel cell 43 surface binding target of MERS-CoV that facilitates MERS-CoV infection through 44 augmenting the attachment of the virus to the host cell surface. 45 46 on August 6, 2016 by NORTHERN ILLINOIS UNIV http://jvi.asm.org/ Downloaded from Importance 47 Infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) is 48 associated with the highest mortality rate among all known human-pathogenic 49 coronaviruses. Currently, there are no approved vaccines or therapeutics against MERS-50 CoV infection. The identification of carcinoembryonic antigen-related cell adhesion 51 molecule 5 (CEACAM5) as a novel cell surface binding target of MERS-CoV advanced 52 our knowledge on the cell binding biology of MERS-CoV. Importantly, CEACAM5 53 could potentiate the entry of MERS-CoV through functioning as an attachment factor. In 54 this regard, CEACAM5 could serve as a novel target in addition to dipeptidyl peptidase-4 55 (DPP4) in the development of antiviral strategies for MERS-CoV.
Introduction 70
Coronaviruses are enveloped, positive-sense, and single stranded RNA viruses with 71 genome size of approximately 30kb. They belong to the Coronaviridae family under the 72 order of Nidovirales and are currently classified into four major genera, including the α, 73 β, γ, and δ genus (1). Coronaviruses can infect a wide range of mammals as well as birds 74
(2). The broad species tropism is predominantly attributed to the high diversity in 75 receptor usage across different coronaviruses. To date, six coronaviruses are known to 76 infect humans and they utilize different surface molecules for cell entry. In particular, 77 human coronavirus 229E (HCoV-229E) binds aminopeptidase N (APN) (3) and human 78 coronavirus OC43 (HCoV-OC43) binds O-acetylated sialic acid (4). Severe acute 79 respiratory syndrome coronavirus (SARS-CoV) (5) and human coronavirus NL63 80 (HCoV-NL63) (6) both binds angiotensin I converting enzyme 2 (ACE2). The receptor 81 for human coronavirus HKU1 (HCoV-HKU1) has not been defined. However, O-82 acetylated sialic acid has been suggested as an attachment factor that contributes to the 83 binding of HCoV-HKU1 to the cell surface (7) . The Middle East respiratory syndrome 84 coronavirus (MERS-CoV) is the sixth coronavirus known to cause infection in humans 85 (8). Intriguingly, MERS-CoV utilizes a unique cellular receptor, dipeptidyl peptidase-4 86 using the Dynabeads Untouched Human T cells Kit (Invitrogen, USA) as we previously 139 described (25) . Isolated T cells were maintained in Roswell Park Memorial Institute 140 medium (RPMI)-1640 supplemented with 10% FBS, 100 ug/ml streptomycin, 100 U/ml 141 penicillin, 1% sodium pyruvate, 1% non-essential amino acids, and were used 142 immediately for infection. with serum free DMEM supplemented with 100 unit/ml penicillin and 100 µg/ml 147 streptomycin. Three days post virus inoculation, culture supernatants were collected, 148 aliquoted, and stored at -80ºC. To determine virus titer, aliquots of MERS-CoV were 149 used for plaque assays on confluent VeroE6 cells in 24-well plates. In brief, MERS-CoV 150 stocks were 10-fold serially diluted in DMEM. Diluted MERS-CoV was then added to 151 duplicate wells of 24-well plates at a volume of 200μl. After inoculating for 1 hour at 152 37ºC, the inoculum was removed from the wells and an agarose overlay was added to the 153 cells. The cells would then be incubated for approximately 72 hours. To count plaques, 154 the cells were fixed with 4% paraformaldehyde for 5 hours and stained with crystal 155 violet. 156 the in-house mouse anti-MERS-CoV spike immune serum or with a rabbit anti- CoV spike antibody (Sino Biological, China) . Secondary antibodies including Alexa 163 KpnI site to the C-terminal XhoI site was subcloned to generate full-length S in pcDNA 171 3.1(+). For the construction of the S1 plasmid (amino acids 1-925), the 5' forward primer 172 sequence containing a BSSHII site (5'GCGCGCCACCATGATACACTC 173 AGTGTTTCTACTGATGTTC) was used together with the 3' reverse primer (5'-174 GGGCCCATCACCGTCTTCCCACACAGTGGATG) with a ApaI site. The fragment 175 was PCR amplified and cloned into the pSFV1 vector (kindly provided by Dr. P. 176 Liljestrom) with the C terminus fused in-frame with the FLAG sequence (DYKDDDDK) 177 and resulting in the plasmid pSFV-MERS-CoV-S1-FLAG. For the construction of the 178 pSFV-DPP4-6xHis plasmid, forward primer containing a BSSHII site (5'-179 GCGCGCCACCATGAAGACACCGTGGAAGG) and reverse primer with a ApaI site 180 (5'-GGGCCCAGGTAAAGAGAAACATTGTTTTATG) were used. The fragment was 181 cloned into the pSFV1 vector with the 6x His sequence (HHHHHH) fused in-frame at the 182 C-terminus. For the construction of the pcDNA-DPP4, the forward primer containing a 183 SW32Ti at the speed of 32,000 rpm for 1 hour at 4ºC (17). The p24 concentrations were 202 quantified with a p24 antigen enzyme-linked immunoassay kit (Cell Biolabs, USA) and 203 stored in aliquots at -80ºC. Pseudovirus titer was quantified in unit of lentiviral particle 204 (LP) per ml according to the manufacturer's instruction. 205
MS/MS analysis carried out in the Center for Genomic Sciences at the University of 230
Hong Kong as we previously described (26) . 231 232 Co-immunoprecipitation (co-IP). Co-IP was performed using anti-FLAG M2 affinity 233 gel beads (Sigma, USA) or V5 antibody pre-adsorbed to Protein A+G sepharose (Thermo 234 Scientific, USA). Cell lysates were harvested in lysis buffer , 235
150mM NaCl, 1% Triton X-100, 0.1% NP-40, protease and phosphatase inhibitors 236 cocktails, Roche). Lysed cells were incubated on ice for 15-30 min and then centrifuged. 237
Supernatant was added to antibody-coupled beads or anti-FLAG affinity gel beads and 238 incubated overnight at 4ºC. Beads were washed three times with lysis buffer and Western 239 blot was performed. Immunoprecipitated products or cell lysates were mixed with SDS 240 loading buffer and heated at 95ºC for 10 min. Samples were fractionated in 10% SDS-241 PAGE and then transferred onto PVDF membranes (GE Healthcare, UK). After blocking 242 overnight with 10% skim milk, membranes were incubated with corresponding primary 243 antibodies and then with infra-red dye conjugated secondary antibodies (LI-COR, USA). 244
Membranes were scanned with an Odyssey Imaging System (LI-COR, USA from Roche as we previously described (27, 28) . In the RT reactions, reverse primers 252 against the NP gene of MERS-CoV were used to detect cDNA complementary to the 253 positive strand of viral genomes. The following sets of primers were used to detect NP in 254 qPCR. 255
Antibody blocking assays. The antibody blocking assay based on the MERS-S-260 pseudotyped virus was performed by measuring the infection of target cells with the use 261 of luciferase as a reporter gene (17). In brief, antibody was diluted to 2µg/ml in serum 262 free culture medium and incubated with Calu3 cells for 1 hour at 37ºC. Pseudotyped virus 263 was added to target cells at a ratio of 100 lentiviral particle (LP) per cell and the inoculum 264 was replaced with fresh medium with 10% FBS after 1 hour. Luciferase activity was 265 determined at 48 hours post infection. For the antibody blocking assay based on the 266 infectious MERS-CoV, Calu3 cells were pre-incubated with rabbit polyclonal anti-267 CEACAM5 at different concentrations ranging from 0.5-4 µg/ml. Rabbit polyclonal anti-268 DPP4 at 4 µg/ml and rabbit IgG at 4µg/ml were included as controls. After pre-incubating 269 with the antibodies for 1 hour at 37ºC, the cells were challenged with MERS-CoV at 1 270 MOI for 1 hour at 37ºC in the presence of antibodies. The cells were subsequently 271 washed with PBS and lysed with RLT with 40mM dithiothreitol (DTT). To determine the 272 impact of antibody blocking on MERS-CoV multi-cycle replication, Huh7 cells were pre-273 incubated with 2 µg/ml anti-CEACAM5 antibody, anti-DPP4 antibody, or rabbit IgG. Lipofectamine 3000 (Thermo Fisher, USA) following manufacturer's manual. In brief, 293
Huh7 cells were transfected with 100µM siRNA for two consecutive days. At 24 hours 294 post the second siRNA transfection, the cells were challenged with MERS-CoV at 1 MOI 295 for 2 hours at 37ºC. Following the incubation, the cells were washed with PBS and lysed 296 in RLT with 40mM DTT. The virus copy number was determined with qPCR. 297 Flow cytometry. All samples were detached with 10mM EDTA and fixed in 4% 299 paraformaldehyde. Cell permeabilization for intracellular staining was performed with 300 0.1% Triton X-100 in PBS. Immunostaining for flow cytometry was performed following 301 standard procedures as we previously described (29). The flow cytometry was performed 302 using a BD FACSCanto II flow cytometer (BD Biosciences, USA) and data was analyzed 303
using FlowJo vX (Tree Star, USA). 304 305
Flow cytometry of BHK21 cells with overexpression of DPP4 and CEACAM5. 306
BHK21 cells were transfected with pSFV-DPP4 or pcDNA-CEACAM5. The transfected 307 cells were inoculated with MERS-CoV at 48 hours post transfection. To determine virus 308 entry, the cells were inoculated with MERS-CoV at 5 MOI at 37ºC for 2 hours. After 2 309 hours, the cells were washed with PBS and incubated for another 4 hours. At 6 hours 310 post-infection, the cells were washed extensively with PBS, fixed in 4% 311 paraformaldehyde, and immunolabeled for flow cytometry. To determine virus 312 attachment, the cells were inoculated with MERS-CoV at 30 MOI at 4ºC for 2 hours. 313
After 2 hours, the cells were washed with PBS, fixed in 4% paraformaldehyde, and 314 immunolabeled for flow cytometry. 
Statistical comparison between different groups was performed by Student's t-test using 328
GraphPad Prism 6. Differences were considered statistically significant when p < 0.05. 329
330
Results 331
Identification of CEACAM5 as a cell surface binding protein of MERS-CoV 332
To probe for potential cell surface factors that can interact with MERS-CoV, we 333 employed the virus overlay protein binding assay (VOPBA), which we have previously 334 utilized to identify host cell surface binding proteins of the influenza A virus (26). In 335 brief, membrane proteins on A549 cells were selectively biotinylated and separated from 336 non-biotinylated intracellular proteins by binding to avidin agarose (23). The biotinylated 337 A549 surface extracts separated in 4-12% gradient SDS NuPAGE gel were transferred to 338 PVDF membrane before incubating with MERS-S-pseudotyped viruses for 2 hours at 339 room temperature ( Figure 1A ). Subsequently, reactive signals were revealed with a rabbit 340 polyclonal antibody against MERS-CoV spike. As shown in figure Figure 2C ). Notably, despite being recognized by the human 368 DPP4 antibody, the DPP4 on hamster and mouse cells do not support MERS-CoV entry 369 (30). In contrast to DPP4, our data demonstrated that the expression of CEACAM5 was 370 more restricted. Among the six human cell lines we analyzed, CEACAM5 expression 371 was detected on A549, Calu3, and Huh7 cells (Figure 2A ). At the same time, little to no 372 CEACAM5 expression was detected on AD293, BEAS2B, and Caco2 cells (Figure 2A) . 373 Importantly, CEACAM5 expression was also detected on human primary T cells ( Figure  374 2B). However, no human CEACAM5 ortholog was expressed on VeroE6, BHK21, and 375 L929 cells ( Figure 2C ). Quantitatively, CEACAM5 expression was detected 376 predominantly on cells that are highly susceptible to MERS-CoV infection, which 377 include Calu3, Huh7, A549, and T cells ( Figure 2D and Figure 2E ). Thus, our data 378 supported the notion that CEACAM5 might be an important surface binding protein, 379 which could facilitate MERS-CoV entry. 380
381

CEACAM5 is co-expressed with DPP4 in human lung tissues 382
To further verify the physiological relevance of CEACAM5 in MERS-CoV infection, we 383 evaluated the expression of CEACAM5 in human lung tissues and compared the 384 expression with that of DPP4 by immunofluorescent microscopy. Our result revealed that 385 CEACAM5 could be readily detected in the epithelial cells in various regions of the 386 human lung tissues ( Figure 3 ). In particular, colocalization between CEACAM5 and 387 DPP4 was observed in the bronchial epithelium ( Figure 3A ) but appeared to be more 388 extensive in the epithelium of small airways ( Figure 3B ). The colocalization between 389 CEACAM5 and DPP4 was also detected in alveoli ( Figure 3C To validate our VOPBA-LC-MS/MS findings, the direct interaction between MERS-CoV 397 S1 and CEACAM5 was characterized by co-immunoprecipitation (co-IP). BHK21 cells 398
were either transfected with a CEACAM5-V5 expression vector or a control vector 399 tagged with V5. The surface and intracellular expression of transfected CEACAM-V5 400 was verified with flow cytometry ( Figure 4A ). Transfected BHK21 cells were then 401 immunoprecipitated with either MERS-CoV S1-FLAG or E. coli bacterial alkaline instead of MERS-CoV S1-FLAG ( Figure 4C ). To this end, CEACAM5-V5 or empty 411 vector transfected BHK21 cell lysates were immunoprecipitated with anti-V5 pre-412 adsorbed protein A/G sepharose, spun down, washed, and incubated with purified 413 on August 6, 2016 by NORTHERN ILLINOIS UNIV http://jvi.asm.org/ Downloaded from MERS-CoV S1-FLAG or BAP-FLAG. Western blot detection with anti-FLAG showed 414 that CEACAM5-V5 interacted with MERS-CoV S1-FLAG ( Figure 4C , upper panel, lane 415 1) but not BAP-FLAG ( Figure 4C, upper panel, lane 2) . As a negative control, the V5 416 empty vector did not pull down MERS-CoV S1 ( Figure 4C, upper panel, lane 3) . In line 417 with the flow cytometry data from Figure 2C , the antibody against human CEACAM5 418 did not pick up any signal from the BHK21 cell lysates ( Figure 4C, lower panel, lane 3) . 419
To further validate our findings and avoid the use of overexpressed or tagged fusion 420 proteins, we performed endogenous co-IP on non-transfected Huh7 cells infected with 421 IgG. The interaction between MERS-CoV spike and CEACAM5 was confirmed with 426 reciprocal co-IP using antibody against MERS-CoV spike. In this regard, endogenous 427 CEACAM5 was detected from infected samples immunoprecipitated with antibody 428 against MERS-CoV spike but not from uninfected samples or from infected samples 429 immunoprecipitated with non-specific rabbit IgG ( Figure 4D ). Take together, our co-IP 430 results demonstrated that MERS-CoV S1 could bind specifically to CEACAM5. 431 432
MERS
CEACAM5-specific antibody blocks MERS-CoV entry and spread 433
After confirming the direct interaction between CEACAM5 and MERS-CoV S1, we next 434 
MERS-CoV entry 463
In addition to antibody blocking, we sought to further verify the impact of CEACAM5 464 inhibition on MERS-CoV infection with alternative approaches including protein 465 blocking and siRNA knockdown. In protein blocking assays, MERS-CoV was pre-466 incubated with human recombinant CEACAM5 protein ranging from 5 μg/ml to 40 467 μg/ml. Human recombinant DPP4 protein and human recombinant IgG were included as 468 controls. Calu3 or Huh7 cells were subsequently inoculated for 2 hours with the virus-469 protein mixes. After inoculation, the cells were washed and harvested for viral load 470 quantification with qPCR analysis. Remarkably, our data demonstrated that the human 471 CEACAM5 recombinant protein blocked the entry of MERS-CoV in a dose-dependent 472 manner in both Calu3 ( Figure 6A ) and Huh7 cells ( Figure 6B ). As a control, CEACAM5 473 protein added after MERS-CoV inoculation had no effect on virus entry ( Figure 6C) . 474
Next, we depleted the endogenous expression of CEACAM5 in Huh7 cells with siRNA. 475
The reduction of CEACAM5 surface expression was examined with flow cytometry with 476 no cell permeabilization ( Figure 6D ). As illustrated in figure 6E and figure 6F , siRNA 477 treatment significantly diminished the surface expression of CEACAM5 both in terms of 478 the percentage of CEACAM5 positive cell ( Figure 6E ) as well as the mean fluorescent 479 intensity (MFI) ( Figure 6F) . Notably, when the CEACAM5 siRNA-treated Huh7 cells The result of the entry assessment recapitulated the finding that human DPP4 496 overexpression could support MERS-CoV entry in the otherwise non-permissive BHK21 497 cells. In stark contrast, human CEACAM5-expressing BHK21 cells failed to sustain the 498 entry of MERS-CoV ( Figure 7A and Figure 7B ). In the attachment assessment, our data 499 suggested that while MERS-CoV could attach to the cell surface of BHK21 cells, human 500 DPP4 overexpression increased the amount of attached virus particles by around 3-folds. 501
Intriguingly, in human CEACAM5-expressing BHK21 cells, the amount of attached virus 502 particles was also significantly increased by more than 2-folds ( Figure 7C The spike proteins of coronaviruses are known to bind a broad range of cellular targets 522 including sialic acids, sugars, and proteins (32). It is now clear that MERS-CoV 523 predominantly utilizes DPP4 for cell entry (9). However, additional cellular binding 524 targets of the MERS-CoV spike protein that may augment MERS-CoV entry have not 525 been further explored. In the current study, using the VOPBA-LC-MS/MS approach, we 526 unveiled CEACAM5 as a novel cell surface binding protein of MERS-CoV (Figure 1) . 527
Intriguingly, expression analysis revealed that CEACAM5 were expressed on cell types 528 that are highly permissive to MERS-CoV infection, including Calu3, Huh7, A549, and 529 primary T cells (Figure 2 ). CEACAM5 and DPP4 co-expressed in the human lung, which 530 highlighted the physiologically relevance of CEACAM5 in MERS-CoV entry (Figure 3) . 531
Subsequently, a series of co-IP studies demonstrated the capacity of CEACAM5 in 532 binding to the spike protein of MERS-CoV either in overexpressed or endogenous 533 settings (Figure 4) . Remarkably, when the interaction between CEACAM5 and MERS-534
CoV spike was perturbed with anti-CEACAM5 antibody ( Figure 5 In the context of coronaviruses, previous reports have identified murine CEACAM1 as 563 the principal cellular receptor of the mouse hepatitis virus (MHV) (11). The discovery of 564 CEACAM5 as a cellular binding target of MERS-CoV spike suggested that perhaps cell 565 surface CEACAMs are common binding targets of coronavirus spikes that can be 566 exploited for attachment or entry. It will be tempting to speculate that other members of 567 the coronavirus family can also make use of certain CEACAMs to facilitate infection. 568
Notably, the spike proteins of coronaviruses are capable of binding to multiple cellular 569 targets. As an example, SARS-CoV binds to ACE2 with the spike S1 C-terminal domain 570 (CTD) (36). At the same time, the SARS-CoV spike can also bind DC-SIGN (16), DC-571 SIGNR (16), and L-SIGN (15). Similarly, TGEV binds to APN with the spike S1 CTD 572 on August 6, 2016 by NORTHERN ILLINOIS UNIV http://jvi.asm.org/ Downloaded from (10) but the virus is also capable of binding to cell surface sugars and sialic acids using 573 the N-terminal domain (NTD) of S1 (37). Since MHV binds CEACAM1 at the first 330 574 amino acids of the S1 NTD (38), one may postulate that MERS-CoV spike may similarly 575 bind CEACAM5 with the NTD of S1. In this regard, the CEACAM5-S1 NTD interaction 576 may orchestrate with the DPP4-S1 CTD interaction (36, 39) and facilitates the infection 577 of MERS-CoV. Importantly, the epitopes from the receptor-binding domain of MERS-578
CoV S1 are known to trigger the production of potent neutralization antibodies. It is 579 potentially feasible to include additional epitopes derived from the CEACAM5-binding 580 domain in future vaccine designs, which may further enhance the efficiency of the 581 produced neutralizing antibodies at the same time avoiding potential immunopathological 582 effects as observed from using the full length spike protein (40). 583 584 By definition, a receptor is a cellular factor essential for viral entry and bound by the viral 585 glycoproteins whereas an attachment factor is a cellular factor that can increase the 586 efficiency of virus entry but is not sufficient to render otherwise refractory cells 587 susceptible to infection. In line with the definitions, CEACAM5 expression was 588 predominantly detected in cell types highly susceptible to MERS-CoV infection, 589
including Huh7, Calu3, and T cells. Therefore, the expression of CEACAM5 may in part 590 contribute to the permissiveness of a certain cell type in addition to DPP4. Our data 591 showed that the expression of CEACAM5 did not confer infectivity by MERS-CoV to 592 the non-permissive BHK21 cells. However, the expression of CEACAM5 markedly 593 increased the amount of virus particles that were bound to the cell surface. Subsequent 
